SCHEMBL34464780

SCHEMBL34464780

CC1(C)OB(c2ccc(C(=O)NOCc3ccccc3)cc2)OC1(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
CA1 P00915 4/20 0.51
CA2 P00918 4/20 0.51
CA9 Q16790 4/20 0.51
HDAC3 O15379 2/20 0.49
HDAC4 P56524 2/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC2 Q92769 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC11 Q96DB2 2/20 0.49
HDAC8 Q9BY41 2/20 0.49
HDAC6 Q9UBN7 2/20 0.49
HDAC9 Q9UKV0 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
LIPG Q9Y5X9 2/20 0.48
P4HB P07237 1/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9985455 0.95 RAB9A (0.61) RAB9ANPC1CA1CA2CA9
SCHEMBL20214552 0.87 RAB9A (0.62) RAB9ANPC1CA1CA2CA9
SCHEMBL20214793 0.85 CA1 (0.49) RAB9ANPC1CA1CA2CA9
SCHEMBL22071360 0.84 CA1 (0.54) RAB9ANPC1CA1CA2CA9
SCHEMBL20214628 0.83 HDAC3 (0.44) RAB9ANPC1CA1CA2CA9
SCHEMBL20214591 0.83 HDAC1 (0.54) RAB9ANPC1CA1CA2CA9
SCHEMBL22028052 0.82 HDAC1 (0.52) RAB9ANPC1CA1CA2CA9
SCHEMBL20226849 0.82 HDAC1 (0.52) RAB9ANPC1CA1CA2CA9
SCHEMBL20214809 0.82 CA1 (0.46) RAB9ANPC1CA1CA2CA9
SCHEMBL2355046 0.81 CA2 (0.70) RAB9ACA1CA2CA9HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE BAERENKRAFT THERAPEUTICS LLC (US) 2026-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE HDAC6, HDAC3, HDAC1 RAB9A 521/4885NPC1 1415/4885CA1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.